Jason O'Byrne insider trades: Vir Biotechnology (VIR) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jason reports to the SEC
Open-market buys and sales
2 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 23, 2026 | VIR | ↓ Sell | 2,089 | $7.45 | $16K | Direct | Feb 24, 2026 (1d) |
| Nov 17, 2025 | VIR | ↓ Sell | 6,799 | $5.56 | $38K | Direct | Nov 18, 2025 (1d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other VIR insiders
Open-market trades in the last 12 months
About Jason O'Byrne's insider trades
Jason O'Byrne is EVP & Chief Financial Officer at Vir Biotechnology (VIR). Since Nov 17, 2025, Jason has reported no open-market purchases and 2 sales worth $53K on SEC Form 4. In the last 12 months: 2 sales ($53K).
Their filings also include grants and awards (7 filings), other transactions (1 filing), option exercises (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every VIR insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.